News Release

Novel mechanism uncovered: PRMT1 advances gastric cancer progression via β-catenin signaling

Peer-Reviewed Publication

Chongqing Medical University

Schematic diagram showing PRMT1-enhanced gastric cancer metastasis mediated by the β-catenin signaling pathway in vitro and in vivo.


In the cytoplasm, KTN1 inhibits K48-linked polyubiquitination of PRMT1 by decreasing the interaction between TRIM48 and PRMT1. Then, in the nucleus, PRMT1 recruits MLXIP to the β-catenin promoter and transcriptionally activates the β-catenin signaling pathway. PRMT1 promotes gastric cancer cell proliferation, migration, and invasion of in vitro and tumor growth and metastasis in vivo.

view more 

Credit: Genes & Diseases

In a study published in the journal Genes & Diseases, researchers from Southwest University, and Southwest Medical University investigated PRMT1, a protein previously known to be overexpressed in gastric cancer cells. Using short hairpin RNA (shRNA) technology, they reduced the expression of PRMT1 in HGC-27 and MKN-45 cells. Additionally, they treated the cells with PRMT1 inhibitors to study the effects on cell proliferation and migration. The findings have unveiled a groundbreaking mechanism through which Protein arginine methyltransferase 1 (PRMT1) promotes the proliferation and spread of gastric cancer (GC) cells. Analysis from the Oncomine and The Cancer Genome Atlas (TCGA) databases revealed a pronounced overexpression of PRMT1 in gastric cancer tissues, which is associated with poor patient prognosis. This overexpression plays a significant role in gastric cancer progression, as silencing PRMT1 diminishes the proliferation and migration rate of GC cells. Intriguingly, PRMT1 directly binds to and activates the β-catenin signaling pathway, a key player in cell growth and metastasis, by targeting its promoter. The study also identified MLXIP, a transcription factor, as a PRMT1-binding protein, suggesting that PRMT1 possibly recruits MLXIP to the β-catenin promoter, further underlining its intricate role in GC dynamics. Additionally, Kinectin (KTN1) has been found to interact with PRMT1, offering another layer of regulation that could impact PRMT1's function in gastric cancer.The findings point toward new potential therapeutic targets for gastric cancer.

The study unveils a novel molecular mechanism of PRMT1's role in advancing gastric cancer, mediated by the β-catenin signaling pathway. The identified PRMT1-MLXIP-β-catenin axis could become a pivotal target for future therapeutic strategies against gastric cancer. These findings could pave the way for developing gene therapies targeting PRMT1 or associated pathways, offering hope to millions diagnosed with this aggressive cancer.





Original Source URL

Funding information

The National Natural Science Foundation of China (82203339), The Postdoctoral Research Foundation of China (2021M692679), The Chongqing Postdoctoral Science Foundation (China) (7820100607), The Natural Science Foundation Project of Chongqing (China) (cstc2021jcyj-bsh0067 and cstc2022ycjh-bgzxm0145).

About Genes & Diseases

Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.